The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms
- PMID: 38825869
- DOI: 10.1177/02698811241254832
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms
Abstract
Background: The highly selective 5-HT1A serotonin receptor "biased" agonists NLX-101 and NLX-204 display, like ketamine, potent and efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model with systemic (i.p.) administration. They rapidly (within 1 day) reverse anhedonia (i.e., CMS-induced sucrose consumption deficit), attenuate working memory deficit (novel object recognition: NOR), and decrease anxiety behavior in the elevated-plus maze (EPM).
Aims: Here, we sought to explore the contribution of prefrontal cortex (PFC) 5-HT1A receptor activation in the RAAD activity of NLX compounds.
Results/outcomes: In male Wistar rats, unilateral PFC microinjections of NLX-204 and NLX-101 (16 µg), like ketamine (10 µg), reproduced the effects of their systemic administration: they reversed CMS-induced sucrose consumption deficit, attenuated anxiety (EPM), and reduced working memory deficits (NOR). In addition, unilateral PFC microinjections of the selective 5-HT1A antagonist, WAY-100,635 (2 µg), attenuated the beneficial effects of systemic NLX-204 and NLX-101 (0.16 mg/kg i.p.) in the sucrose intake and NOR models, indicating that these compounds exert their RAAD activity specifically through activation of PFC 5-HT1A receptors.
Conclusions/interpretation: These data indicate that 5-HT1A receptor biased agonists share with ketamine a common neuroanatomical site for RAAD activity, which can be obtained not only by targeting glutamatergic/NMDA neurotransmission (ketamine's primary mechanism of action) but also by activating 5-HT1A receptors, as is the case for the NLX compounds. The present observations also reinforce the notion that biased agonism at 5-HT1A receptors constitutes a promising strategy to achieve RAAD effects, with additional benefits against cognitive deficits and anxiety in depressed patients, without ketamine's troublesome side effects.
Keywords: Serotonin 5-HT1A receptors; biased agonist; chronic mild stress; depression; ketamine.
Conflict of interest statement
Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.N.-T. and R.D. are employees and stockholders of Neurolixis. M.P., P.G., E.L., and M.L. declare that they have no actual or potential conflict of interest.
Similar articles
-
[18F]FDG PET metabolic patterns of the rapid-acting antidepressant effects of NLX-101, a 5-HT1A receptor biased agonist.Transl Psychiatry. 2025 Sep 1;15(1):336. doi: 10.1038/s41398-025-03572-4. Transl Psychiatry. 2025. PMID: 40890135 Free PMC article.
-
The antidepressant-like activity of ketamine in the rat chronic mild stress model requires activation of cortical 5-HT 1A receptors.Behav Pharmacol. 2025 Jun 1;36(4):182-188. doi: 10.1097/FBP.0000000000000809. Epub 2024 Dec 16. Behav Pharmacol. 2025. PMID: 39718040
-
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, display ketamine-like RAAD and anti-TRD activities in rat CMS models.Psychopharmacology (Berl). 2023 Nov;240(11):2419-2433. doi: 10.1007/s00213-023-06389-5. Epub 2023 Jun 13. Psychopharmacology (Berl). 2023. PMID: 37310446 Free PMC article.
-
Augmentation Therapy With Serotonin 5-HT1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies.Neuropsychopharmacol Rep. 2025 Jun;45(2):e70023. doi: 10.1002/npr2.70023. Neuropsychopharmacol Rep. 2025. PMID: 40421605 Free PMC article. Review.
-
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.Cochrane Database Syst Rev. 2021 Oct 8;10(10):CD011611. doi: 10.1002/14651858.CD011611.pub3. Cochrane Database Syst Rev. 2021. PMID: 34623633 Free PMC article.
Cited by
-
Trends in research on novel antidepressant treatments.Front Pharmacol. 2025 Jan 27;16:1544795. doi: 10.3389/fphar.2025.1544795. eCollection 2025. Front Pharmacol. 2025. PMID: 39931695 Free PMC article. Review.
-
Discovery of NLX-266, an Orally Available and Metabolically Stable ERK1/2-Biased 5-HT1AR Agonist with Superior Antidepressant and Antiparkinsonian Activity.J Med Chem. 2025 May 8;68(9):9706-9722. doi: 10.1021/acs.jmedchem.5c00484. Epub 2025 Apr 23. J Med Chem. 2025. PMID: 40267318 Free PMC article.
-
The Pathogenesis and Medical Treatment of Depression: Opportunity and Challenge.Neurol Int. 2025 Aug 4;17(8):120. doi: 10.3390/neurolint17080120. Neurol Int. 2025. PMID: 40863989 Free PMC article. Review.
-
[18F]FDG PET metabolic patterns of the rapid-acting antidepressant effects of NLX-101, a 5-HT1A receptor biased agonist.Transl Psychiatry. 2025 Sep 1;15(1):336. doi: 10.1038/s41398-025-03572-4. Transl Psychiatry. 2025. PMID: 40890135 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous